JHL's Principal Activity is the development and provision of healthcare industry service technologies and the development of integrated dispensing automation systems for the pharmaceutical and healthcare sectors.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||+151.43%|
|vs ASX 200 (1yr)||+114.03%|
|ASX Rank||2123 of 2,564|
|Sector Rank||170 of 177|
Jayex Healthcare Limited (JHL) is a provider in the United Kingdom and Australia of integrated healthcare services delivery platforms, incorporating the Company's four interconnected and proprietary technologies, being: Enlighten patient workflow platform; Appointuit patient engagement solution; Pharmacy Delivery and BluePoint remote pharmacy prescription processing and dispensing terminal.
No incorporation details available.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Mr Nicholas Harper||Non-Executive Director||Sep 2020||
Mr Nicholas Harper
Mr Harper has over thirty years experience working in software development. During that time, he has worked in the public sector (local government), investment banking and the aviation sector in a range of roles and with responsibilities. Nick has worked on implementing and maintaining range of software systems from batch valuation systems to real-time data processing. He also has experience of project management and software team building.
|Mr Michael Denis Boyd||Executive Chairman,Executive Director||May 2017||
Mr Michael Denis Boyd
Executive Chairman,Executive Director
Mr Boyd has been involved in the creation of enterprises, both in the private and public sectors, for over 27 years. Mr Boyd has been in developing and growing new projects in areas including healthcare, telecommunications and finance. After leaving Sonic he started Foundation Healthcare, growing it to over 800 healthcare professionals before it was acquired by Sonic. He was also a founding partner of Iridium Satellite bringing it out from bankruptcy to now a listed company.
|Mr Michael Chan||Non-Executive Director||Mar 2017||
Mr Michael Chan
Mr Chan has experience in based financial services for the past 30 years with hands on knowledge in both consumer and commercial segments. He is the founder and Managing Director at AMG Corporate Pty Ltd, a holder of an Australian Credit Licence which is primarily a debt advisory business. Prior to establishing AMG, he worked in key roles involved with business development and marketing at range of companies, both in the private and public sectors. He has had a past affiliation with Make a Wish Foundation and more recently is the founder and chairman of The Mate Foundation - a men's health initiative with its principal purpose to help raise awareness of men's health diseases, which is due to launch shortly. He has over the years also undertaken work for range of other charities and causes in his community. He is a member of the Risk Committee.
|Ms Melanie Jaye Leydin||Company Secretary||Aug 2015|
|Mr Brian Renwick||Non-Executive Director||Jul 2009||
Mr Brian Renwick
Mr Renwick is experienced across the pharmaceutical and healthcare sector in Australia. His involvement with sector commenced in finance roles that led into commercial analysis, marketing and sales. From this commercial experience in the manufacturing end of the supply chain he moved into the wholesaling segment with various business development roles in retail and hospital pharmacy. Mr Renwick's roles has into commercial and business development including as general manager for a corporate pharmacy business. He has completed two Business Development roles within the CSL Limited group. With his detailed commercial knowledge and experience across the healthcare segment, Brian has provided consulting advice to Jayex since 2006 and is an important member of the team. He is a Chairman of the Risk Committee.
|Nathan Woodard||Chief Financial Officer||N/A|
JHL directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|13/10/20||Michael Boyd||Buy||+3,000,000||$0.05||$150,000||As advised by the company|
|30/09/20||Michael Boyd||Buy||+1,500,000||$0.035||$52,500||On-market trade|
|30/06/20||Michael Chan||Buy||+24,962||$0.018||$449||On-market trade|
|29/06/20||Michael Chan||Buy||+123,648||$0.018||$2,225||On-market trade|
|13/11/19||Michael Boyd||Buy||+150,000||$0.039||$5,791||On-market trade|
|12/11/19||Michael Boyd||Buy||+64,831||$0.039||$2,503||On-market trade|
|04/04/19||Michael Boyd||Buy||+57,541||$0.035||$2,014||On-market trade|
|02/04/19||Michael Boyd||Buy||+23,199||$0.035||$812||On-market trade|
|29/03/19||Michael Boyd||Buy||+19,128||$0.035||$669||On-market trade|
|28/03/19||Michael Boyd||Buy||+71,487||$0.035||$2,502||On-market trade|
|27/03/19||Michael Boyd||Buy||+28,645||$0.035||$1,003||On-market trade|
|26/03/19||Michael Boyd||Buy||+101,173||$0.035||$3,541||On-market trade|
|25/03/19||Michael Boyd||Buy||+98,827||$0.035||$3,459||On-market trade|
|13/09/18||Michael Chan||Buy||+200,000||$0.019||$3,800||On-market trade|
|05/06/18||Michael Chan||Buy||+55,315||$0.024||$1,328||On-market trade|
|04/06/18||Brian Renwick||Issued||1,130,653||$0.02||$22,500||Director remuneration|
|04/06/18||Agam Jain||Issued||3,123,417||$0.02||$62,156||Director remuneration|
|01/06/18||Agam Jain||Buy||+226,156||$0.02||$4,523||On-market trade|
|20/04/18||Agam Jain||Buy||+749,110||$0.018||$13,484||On-market trade|
The current holdings of JHL directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Vector London Ltd||10/03/2021||19,003,378||9.44|
|Covenant Holdings (WA) Pty Ltd||10/03/2021||77,912,910||38.69|
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
|Year||Closing Price||Last Trade|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.